• Arrowhead Pharmaceuticals presented interim Phase 1/2a data on RNAi candidate ARO-INHBE at EASL 2026.
• The study showed meaningful reductions in liver fat in adults with obesity, supporting potential use in MASH.
• Combination dosing with low-dose tirzepatide improved liver fat and visceral fat outcomes versus tirzepatide alone.
• Safety profile looked manageable, with mostly mild adverse events and no discontinuations tied to treatment.
• Regulatory discussions are under way to shape Phase 2 study designs in obesity and MASH.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260527903149) on May 27, 2026, and is solely responsible for the information contained therein.